Global Cancer Gene Therapy Market Growth, Size, Trends Analysis - By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Global Cancer Gene Therapy Market Introduction and Overview

According to SPER market research, 'Global Cancer Gene Therapy Market Size- By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Cancer Gene Therapy Market is predicted to reach 26.62 billion by 2034 with a CAGR of 19.16%.

Cancer gene therapy is a cutting-edge treatment strategy that focuses on altering or engineering a patient's genetic material to combat cancer. This approach may involve repairing faulty genes, activating genes that suppress tumor growth, or inserting new genes to boost the immune system's ability to detect and eliminate cancer cells. By directly targeting the genetic basis of cancer, gene therapy offers a more precise and potentially less harmful alternative to conventional treatments such as chemotherapy and radiation.

Restraints: The cancer gene therapy market encounters several significant challenges that may limit its broad adoption and advancement. A primary concern is the high cost associated with research, development, and treatment, which can make these therapies unaffordable for many and strain healthcare systems. Moreover, navigating complex regulatory frameworks and prolonged approval timelines often delays the introduction of new therapies.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product Therapy, By End Use

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals Inc.

Global Cancer Gene Therapy Market Segmentation:

By Product Therapy: Based on the Product Therapy, Global Cancer Gene Therapy Market is segmented as; Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer.

By End Use: Based on the End Use, Global Cancer Gene Therapy Market is segmented as; Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25139

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Cancer Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Gene Therapy Market

7. Global Cancer Gene Therapy Market, By Product Therapy 2021-2034 (USD Million)

7.1. Oncolytic Virotherapy
7.2. Gene Induced Immunotherapy
7.3. Gene Transfer

8. Global Cancer Gene Therapy Market, By End Use 2021-2034 (USD Million)

8.1. Research Institutes
8.2. Biopharmaceutical Companies
8.3. Diagnostic Centers
8.4. Others

9. Global Cancer Gene Therapy Market, 2021-2034 (USD Million)

9.1. Global Cancer Gene Therapy Market Size and Market Share

10. Global Cancer Gene Therapy Market, By Region, 2021-2034 (USD Million)

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. Abeona Therapeutics Inc.
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Asklepios BioPharmaceutical Inc.
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Altor Bioscience Inc.
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Bluebird bio Inc.
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. BioCancell Inc.
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. CelgeneInc.
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Elevate BioInc.
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. GlaxoSmithKlineInc.
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Genelux Corporation
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. GenVec
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Introgen TherapeuticsInc.
- 11.11.1. Company details
- 11.11.2. Financial outlook
- 11.11.3. Product summary
- 11.11.4. Recent developments
11.12. OncoGenex Pharmaceuticals Inc.
- 11.12.1. Company details
- 11.12.2. Financial outlook
- 11.12.3. Product summary
- 11.12.4. Recent developments
11.13. Others